EP2207903A4 - Selbstanlagernde mizellenähnliche nanopartikel zur systemischen genzuführung - Google Patents

Selbstanlagernde mizellenähnliche nanopartikel zur systemischen genzuführung

Info

Publication number
EP2207903A4
EP2207903A4 EP08847078A EP08847078A EP2207903A4 EP 2207903 A4 EP2207903 A4 EP 2207903A4 EP 08847078 A EP08847078 A EP 08847078A EP 08847078 A EP08847078 A EP 08847078A EP 2207903 A4 EP2207903 A4 EP 2207903A4
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
self
gene delivery
systemic gene
micelle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08847078A
Other languages
English (en)
French (fr)
Other versions
EP2207903A1 (de
Inventor
Young Tag Ko
Amit Kale
Vladimir P Torchilin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeastern University Boston
Original Assignee
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeastern University Boston filed Critical Northeastern University Boston
Publication of EP2207903A1 publication Critical patent/EP2207903A1/de
Publication of EP2207903A4 publication Critical patent/EP2207903A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
EP08847078A 2007-11-09 2008-11-10 Selbstanlagernde mizellenähnliche nanopartikel zur systemischen genzuführung Withdrawn EP2207903A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US262607P 2007-11-09 2007-11-09
PCT/US2008/012660 WO2009061515A1 (en) 2007-11-09 2008-11-10 Self-assembling micelle-like nanoparticles for systemic gene delivery

Publications (2)

Publication Number Publication Date
EP2207903A1 EP2207903A1 (de) 2010-07-21
EP2207903A4 true EP2207903A4 (de) 2012-02-15

Family

ID=40626108

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08847078A Withdrawn EP2207903A4 (de) 2007-11-09 2008-11-10 Selbstanlagernde mizellenähnliche nanopartikel zur systemischen genzuführung

Country Status (9)

Country Link
US (1) US20100285111A1 (de)
EP (1) EP2207903A4 (de)
JP (1) JP2011503070A (de)
CN (1) CN101970687A (de)
AU (1) AU2008325122A1 (de)
BR (1) BRPI0820302A2 (de)
CA (1) CA2703852A1 (de)
MX (1) MX2010005089A (de)
WO (1) WO2009061515A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539962B2 (ja) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
DK2299953T3 (en) 2008-07-14 2017-06-19 Polypid Ltd CARBON COMPOSITION FOR MEDICINAL PRODUCTS WITH CONTINUOUS EXPOSURE
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
EP2453911A1 (de) * 2009-04-30 2012-05-23 Genetic Immunity Kft Immunogene nanomedizinzusammensetzung sowie ihre herstellung und verwendung
CN105126179B (zh) 2009-07-14 2018-09-25 波利皮得有限公司 持续释放药物载体组合物
SG178369A1 (en) * 2009-08-11 2012-04-27 Agency Science Tech & Res Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
JP5863670B2 (ja) 2010-01-19 2016-02-17 ノースウェスタン ユニバーシティ 核酸および／または他の構成要素を含有している合成ナノ構造体
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
EP3266873A1 (de) * 2010-11-10 2018-01-10 Nigel L. Webb Nuklione und ribocapside
JP6054308B2 (ja) * 2011-02-15 2016-12-27 メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 核酸を細胞へ送達する組成物及び方法
CN102516534B (zh) * 2011-11-14 2013-11-20 上海交通大学 可降解为精胺的聚阳离子及其合成方法、纳米颗粒
AU2013266232B2 (en) * 2012-05-23 2017-08-03 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery
KR102152751B1 (ko) * 2012-09-28 2020-09-07 (주)아모레퍼시픽 식물 유래 당단백질을 포함하는 마이크로캡슐
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
WO2014165566A1 (en) * 2013-04-03 2014-10-09 Emory University Hydrophilic particle compositions, processes of production, and uses in dietary management and digestive disorders
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015042585A1 (en) 2013-09-23 2015-03-26 Rensselaer Polytechnic Institute Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
WO2015065773A1 (en) * 2013-11-04 2015-05-07 Northeastern University System for co-delivery of polynucleotides and drugs into protease-expressing cells
CN105939699B (zh) 2013-12-03 2020-10-02 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
KR101568565B1 (ko) * 2014-01-06 2015-11-23 서울대학교산학협력단 이동성이 조절된 탐침이 결합된 지지형 지질 이중층을 포함하는 인공세포막 및 이를 이용하여 분자 간 상호작용을 분석하는 방법
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
WO2015188838A1 (en) 2014-06-13 2015-12-17 University Of Copenhagen Self-assembling structures
CN104258416B (zh) * 2014-09-25 2018-05-25 山东大学 基于寡聚核苷酸共递送药物和基因的纳米载体及制备方法
MX2017004448A (es) 2014-10-06 2017-10-23 Exicure Inc Compuestos anti-factor de necrosis tumoral (tnf).
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
CN108064295A (zh) 2015-01-14 2018-05-22 埃克西奎雷股份有限公司 具有核心基序的核酸纳米结构
WO2017008016A1 (en) * 2015-07-09 2017-01-12 The Board Of Regents Of The University Of Texas System Nanoparticles containing extracellular matrix for drug delivery
KR101741977B1 (ko) * 2016-04-26 2017-05-31 한국교통대학교산학협력단 경구 투여용 유전자 전달을 위한 나노입자 및 이를 포함하는 약학 조성물
AU2017261360A1 (en) 2016-05-06 2018-11-29 Exicure Operating Company Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA
JP2019519501A (ja) * 2016-05-12 2019-07-11 ブライアン ピー． ハンリーＢｒｉａｎ Ｐ． ＨＡＮＬＥＹ ヒトおよび動物における体細胞の大部分へのｃｒｉｓｐｒおよび他の遺伝子治療薬の安全な送達
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
JP7317706B2 (ja) 2016-12-14 2023-07-31 リガンダル インコーポレイテッド 核酸およびタンパク質ペイロード送達のための方法および組成物
KR101796036B1 (ko) * 2016-12-29 2017-11-10 주식회사 무진메디 Cas9 단백질, KRAS 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀 전달체 조성물 또는 이를 함유하는 KRAS 유전자 변이에 따른 항암제 저항성 대장암 치료제
CN110678202B (zh) * 2017-03-23 2023-04-14 Dnarx公司 用于体内核酸表达的系统和方法
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
WO2019231051A1 (ko) * 2018-06-01 2019-12-05 서강대학교 산학협력단 지질을 이용한 표면 개질을 통해 세포 내 섭취 효율을 향상시킨 나노입자 복합체 및 이의 제조방법
US11197827B2 (en) * 2018-10-31 2021-12-14 Microsoft Technology Licensing, Llc Polynucleotide encapsulation and preservation using self-assembling membranes
KR102198900B1 (ko) * 2019-05-10 2021-01-07 서강대학교 산학협력단 질병 치료용 나노입자 복합체 및 이의 제조방법
CN112574344B (zh) * 2020-12-09 2021-10-15 浙江大学 一种氧化响应去电荷的阳离子聚合物及其制备方法和应用
WO2022157772A1 (en) * 2021-01-21 2022-07-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Rnai nanoparticles and methods of using same in agriculture
CN113633613B (zh) * 2021-07-20 2023-04-25 河南大学 一种siRNA胶束、制备方法、组合物及其应用
CN114306639B (zh) * 2022-01-06 2023-03-31 上海交通大学 一种疏水性药物纳米晶/siRNA共载荷有序结构脂质纳米制剂及制备方法与应用
WO2024050310A1 (en) * 2022-08-29 2024-03-07 Sorrento Therapeutics, Inc. Lipid-coated nanoparticles
CN115624539A (zh) * 2022-12-16 2023-01-20 首都医科大学附属北京朝阳医院 一种脂质纳米颗粒及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20020151060A1 (en) * 2000-09-25 2002-10-17 Board Of Regents, The University Of Texas System PEI: DNA vector formulations for in vitro and in vivo gene delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
JP2001242005A (ja) * 2000-02-28 2001-09-07 Yamato Scale Co Ltd 遠隔アクセス可能な組合せ秤及び組合せ秤システム
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US8496961B2 (en) * 2002-05-15 2013-07-30 Sutter West Bay Hospital Delivery of nucleic acid-like compounds
AU2003230980A1 (en) * 2003-04-18 2004-11-26 Northeastern University Micelle delivery system loaded with a pharmaceutical agent
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20070218122A1 (en) * 2005-11-18 2007-09-20 Protiva Biotherapeutics, Inc. siRNA silencing of influenza virus gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20020151060A1 (en) * 2000-09-25 2002-10-17 Board Of Regents, The University Of Texas System PEI: DNA vector formulations for in vitro and in vivo gene delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009061515A1 *

Also Published As

Publication number Publication date
CA2703852A1 (en) 2009-05-14
CN101970687A (zh) 2011-02-09
EP2207903A1 (de) 2010-07-21
US20100285111A1 (en) 2010-11-11
MX2010005089A (es) 2010-05-21
JP2011503070A (ja) 2011-01-27
BRPI0820302A2 (pt) 2015-05-19
AU2008325122A1 (en) 2009-05-14
WO2009061515A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
EP2207903A4 (de) Selbstanlagernde mizellenähnliche nanopartikel zur systemischen genzuführung
ZA201006260B (en) Delivery particle
ZA201005524B (en) Delivery particle
ZA201100622B (en) Delivery particle
HK1139053A1 (en) Nanoparticle delivery systems for membrane-integrating peptides
GB0706863D0 (en) Nasal delivery
EP2012751A4 (de) Neue nanopartikel zur wirkstofffreisetzung
HK1139171A1 (en) Nanoparticles
IL207569A0 (en) Compositions and methods for drug delivery
EP2244679A4 (de) Nicht-polymer-zusammensetzungen zur kontrollierten arzneimittelabgabe
ZA200904935B (en) Benefit agent delivery compositions
EP2035488A4 (de) Micellen für die arzneistoffzufuhr
EP2419535A4 (de) Freisetzung von oligonukleotid-funktionalisierten nanopartikeln
IL218333A0 (en) Use of dendrimer nanotechnology for delivery of biomolecules into cells
MX2009013925A (en) Hybrid nanoparticles
IL195764A0 (en) Compositions and methods for drug delivery
GB0725321D0 (en) Delivery vehicles
EP2506998A4 (de) Gussausgabedüse
GB0812513D0 (en) Delivery vehicle
GB0811170D0 (en) Nanoparticles
PL2376060T3 (pl) Kompozycje nanocząstek
EP2231694A4 (de) Kationische kern-hülle-peptid-nanopartikel
GB0909435D0 (en) Nanoparticle for biomolecule delivery
GB2471973B (en) Nasal delivery devices
IL221846A0 (en) Compositions for nasal delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: TORCHILIN, VLADIMIR, P.

Inventor name: KALE, AMIT

Inventor name: KO, YOUNG, TAG

A4 Supplementary search report drawn up and despatched

Effective date: 20120118

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/553 20060101ALI20120112BHEP

Ipc: G01N 33/551 20060101ALI20120112BHEP

Ipc: C12Q 1/68 20060101AFI20120112BHEP

17Q First examination report despatched

Effective date: 20150123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150602